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SUMMARY
Malaria is a well known death causing disease 
worldwide. A number of quinoline based antimalarial 
compounds have been synthesized up till now after 
the  discovery of antimalarial character of quinine. 
This review covered a diversified quinoline derivatives 
presented during the last five years, thus highlighting 
their importance as antimalarial agents.
Keywords: Quinoline derivatives; antimalarial ac-
tivity; naturally occurring quinolines; quinine; syn-
thetic quinolines.
RESUMEN
La malaria es una enfermedad conocida en todo el 
mundo que puede causar la muerte. Por el momento 
se han sintetizado una serie de compuestos antimalá-
ricos a base de quinolina tras la síntesis de la quinina. 
Esta revisión ha abarcado una serie diversificada de 
derivados de quinolina que se han presentado en estos 
últimos cinco años, y destaca su importancia como 
agentes antimaláricos.
Palabras clave: Derivados de quinolina; actividad 
antipalúdica; quinolinas de origen natural; quinina; 
quinolinas sintéticas.
RESUM
La malària es una infermetat coneguda arreu del 
mon que pot causar la mort. Fins al moment s’han 
sintetitzat una sèrie de compostos antimalàrics a 
base de quinolina després de la síntesi de la quinina. 
Aquesta revisió ha tractat una sèrie amplia de derivats 
de quinolina que s’han presentat en aquests darrers 
cinc anys, i ressalta la seva importància com agents 
antimalàrics.
Paraules clau: Derivats de quinolina; activitat anti-
palúdica; quinolines d’origen natural; quinina; quino-
lines sintètique
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INTRODUCTION
The history of quinoline based antimalarial 
drugs started from the alkaloid quinine 1 (Fig. 1). 
The natural source of quinine is Cinchona tree 
which was named after the Countess of Chinchon 
because the bark of Cinchona tree was used to cure 
her from malaria first time in 1630s and properties 
of Cinchona tree were discovered. After that, the 
use of Cinchona tree’s bark started to treat malaria 
in different countries in different ways. This dis-
covery developed the interest of scientists to ex-
plore new ways and drugs to cure malaria that led 
to the achievement of novel antimalarial drugs. For 
the first time, Woodward and von Doering provid-
ed the synthetic pathway for quinine 1. Quinidine 
2 (Fig. 1) is also an antimalarial drug which is a 
stereoisomer of quinine1.
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products.Literature elaborated a lot of important quinoline 
based antimalarial agents and among them 4-ami-
noquinoline antimalarial drugs (Fig. 2) are illustrat-
ed in the proceeding lines. Chloroquine 3, sold un-
der the trade name “aralen” is manufactured in the 
form of diphosphate (aralen phosphate, resochin) for 
oral administration. It is also available as intramus-
cular injection in the form of hydrochloride for the 
treatment of malaria induced coma1. Hydroxychlo-
roquine 4, also known as “Plaquenil” and “Axemal” 
in India, shows fast gastrointestinal absorption and 
quick elimination from the body2. Similarly, Amodi-
aquine 5, sold under the trade name “Camoquin” or 
“Flavoquine”, has been used in Africa for the treat-
ment of malaria in combination therapy3. Another 
4-aminoquinoline is quinacrine 6 (substituted acri-
dine), also known as mepacrine. It was introduced 
as antimalarial drug in the mid-1930s4. Now days, 
it is sold under the trade name “Atabrine” for the 
treatment of other diseases. Similarly, there is also 
a variety of 8-aminoquinolines (Fig. 2), among them 
first antimalarial 8-amino quinoline, Pamaquine 7, 
was synthesized in 1924 and used for the treatment 
of malaria in birds in 1926 and then in humans too5. 
Later on, Primaquine 8 was synthesized by Robert 
Elderfield in 19406 and is used for the treatment of 
malaria against P. vivax or P. ovale7. Similarly, Taf-
enoquine 9 is also an 8-aminoquinoline drug, used 
for the treatment and prevention of malaria against 
Plasmodium falciparum8.
In addition, Mefloquine 10 (trade name “Lariam”) 
possessing fluoro and hydroxy groups in its struc-
ture (Fig. 2) has been used for the treatment of Chlo-
roquine-resistant as well as Chloroquine-sensitive 
Plasmodium falciparum malaria9.
NCl
HN
N
3
NCl
HN
N
OH
4
NCl
HN
OH
N
5
N
HN
N
Cl
O
6
N
O
NH
N
7
N
NH
H2N
O
8
N O
NH
O
O
F3C
9
N
CF3
CF3
HO
N
H
10NH2
Fig.
 
2.
 
Structures
 of
 some important
 
quinoline
 
based
 antimalarial
 
drugs.
REVIEW OF LITERATURE
4-Aminoquinolines
As a result of interest in 4-aminoquinoline deriv-
atives, two chromium arene-quinoline half sand-
wich complexes were prepared by Glans et al in 
their laboratory. Screening of compounds for their 
in vitro antimalarial activity against both chloro-
quine-sensitive and chloroquine-resistant strains of 
Plasmodium falciparum proved N1-(7-chloroquin-
olin-4-yl)-N2-(2-((dimethylamino)methyl)benzyl)
ethane-1,2-diamine 11 (IC50 = 33.9nM), twice active 
against malarial parasite than organic ligand alone 
(IC50 = 63.1 nM)10.
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Quinoline based benzoxazines were synthesized and 
evaluated for in vitro and in vivo antimalarial activity 
against chloroquine sensitive (D10), chloroquine re-
sistant (W2) strains of P. falciparum and mouse ma-
laria respectively by Gemma and co-workers. Among 
the synthesized compounds, 3-benzyl-N-(7-chloro-
quinolin-4-yl)-1,2,3,4-tetrahydroquinazolin-7-amine 
12 was mirrored as the most promising antimalarial 
agent with IC50 value 53nM (for D10 strain) and 67 nM 
(for W2 strain)11.
N
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In 2013, Kanishchev and colleagues reported a mul-
ti-step synthesis of new 4-aminoquinoline γ-lactams 
and evaluated their in vitro antimalarial activity 
against Chloroquine-sensitive (3D7) and Chloro-
quine-resistant (W2) strains of P. falciparum. Most of 
the synthesized lactams 13a-f demonstrated excellent 
potential against W2 strain while against 3D7 strain 
only 1-(2-((7-chloroquinolin-4-yl)amino)ethyl)-5-hy-
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droxy-5-((pyridin-4-ylthio)methyl)-3-(2,2,2-trifluo-
roethyl) -1H-pyrrol-2(5H)-one 13d exhibited activi-
ty (IC50 = 89nM) comparable to chloroquine (IC50 = 
750nM (for W2) and 30nM (for  3D7)) (Table 1)12.
N
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R
13a-f
Table 1: Antimalarial potential of compounds 13a-f 
against W2) strain of P. falciparum.
Compound R IC50 (nM) Compound R IC50 (nM)
13a Ph 167 13d 4-Pyridyl 666
13b p-MeOC6H4 173 13e 2-Pyrimidyl 458
13c 2-Pyridyl 218 13f 2-Pyridyl-N-oxide 274
In the next year, a series of 1H-1,2,3-triazole-teth-
ered isatin-7-chloroquinoline and 3-hydroxy-in-
dole-7-chloroquinoline conjugates were synthesized 
by Raj et al. A screening of synthesized compounds 
for their antimalarial activity against chloroquine-re-
sistant W2 strain of Plasmodium falciparum showed 
that the 1-(4-(4-((4-((2-(7-chloroquinolin-4-yl)hy-
drazinyl)methyl)phenoxy)methyl)-1H-1,2,3-triazol-
1-yl)butyl)-3-hydroxyindolin-2-one 14 exhibited 
highest activity (IC50 = 69.0 nM) comparable to the 
reference drug, chloroquine (IC50 = 60.0 nM) but less 
than artemisinin (IC50  = 7.00 nM)13.
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After that, Raj and co-workers synthesized C-3 
thiourea functionalized β-lactams, β-lactam-7-chlo-
roquinoline conjugates and 7-chloroquinoline-thi-
ohydantoin derivatives. An assessment of  their in 
vitro anitimalarial activity against Chloroquine-re-
istant(W2) strain of Plasmodium falciparum re-
vealed that (E)-3-(2-((7-chloroquinolin-4-yl)amino)
ethyl)-5-((E)-3-phenylallylidene)-2-thioxoimidazoli-
din-4-one 15 was found to be the most active with no 
cytotoxicity (IC50 values in nM: 15 = 39.84, Chloro-
quine = 99.0, Artemisinin = 14.0)14.
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Later on, a series of β-amino alcohol tethered 4-ami-
noquinoline-isatin conjugates was synthesized by Ni-
sha et al. A test for their in vitro antimalarial activity 
against chloroquine resistant W2 strain of Plasmo-
dium falciparum concluded that 5-chloro-1-(2-((2-
((7-chloroquinolin-4-yl)amino)ethyl)amino)-3-hy-
droxypropyl)indoline-2,3-dione 16 (IC50 = 11.8 nM) 
and 5-chloro-1-(2-((3-((7-chloroquinolin-4-yl)amino)
propyl)amino)-3-hydroxypropyl)indoline-2,3-dione 
17 (IC50 = 13.5 nM) exhibited significant antimalarial 
efficacy (no toxicity) greater than chloroquine (IC50 = 
36.37 nM)  but less than Artemisinin (IC50 = 4.37 nM)15.
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Further investigation of antimalarial activity of de-
hydroxy-isotebuquine derivatives against Plasmodi-
um berghei by Romero and co-workers revealed that 
derivatives 18, 19 and 20 remarkably inhibited the 
haemozoin formation (%IHF values: 97.080, 98.490 
and 97.250 respectively)16.
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Similarly, a series of novel 4-aminoquinoline-py-
rimidine hybrids was synthesized and evaluated by 
Kumar et al. for their in vitro antimalarial activity 
against a D6-chloroquine sensitive and a W2-chloro-
quine resistant clone of P. falciparum. In the synthe-
sized series, three 4-aminoquinoline-pyrimidine hy-
brids 21-23 showed potent antimalarial activity with 
low cytotoxicity (Table 2)17.
NCl
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Table 2: In vitro antimalarial activity of compounds 
21-23 against D6 and W2 strains of P. falciparum.
Compounds 21 22 23 Chloroquine Pyrimethamine
R 3,5-OMe H 4-F - -
IC50 (D6, µM) 0.033 0.019 0.028 0.035 0.01
IC50 (W2, µM) 0.058 0.144 0.094 0.367 Not tested
Due to excellent potency of 4-anino quinolines, 
Kaur and colleagues obtained hybrids of 5-cyanopy-
rimidine and quinoline. Screening of in vitro antima-
larial activity against NF54-chloroquine sensitive and 
Dd2-chloroquine resistant strains of Plasmodium 
falciparum pointed out 4-((4-((7-chloroquinolin-4-yl)
amino)butyl)amino)-2-(methylthio)-6-(3-nitrophe-
nyl)pyrimidine-5-carbonitrile 24 the best antimalar-
ial agent against Dd2 strain of Plasmodium falcipar-
um with IC50=55.8 nM which is four-fold greater than 
chloroquine having IC50=257.6 nM18.
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In the same year, the synthesized series of novel 4-ami-
noquinoline-1,3,5-triazine derivatives was evaluated by 
Bhat et al. for their in vitro antimalarial activity against 
Chloroquine-sensitive (3D-7) and Chloroquine-re-
sistant (RKL-2) strains of Plasmodium falciparum 
and in vivo antimalarial activity against P. berghei. 
Finally, authors concluded that 2-(4-(4-(2-((7-chloro-
quinolin-4-yl)amino)ethyl)piperazine-1-carbothio-
amido)-6-((4-nitrophenyl)amino)-1,3,5-triazin-2-yl)
hydrazinecarboxamide 25 showed good in vitro and in 
vivo antimalarial potential (Table 3)19.
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Table 3: In vitro and in vivo antimalarial activity of 
compound 25.
Compound % Dead asexual parasites (in vitro)
25
3D-7 RKL-2
5 µg/ml 50 µg/ml 5 µg/ml 50 µg/ml
Chloroquine (0.7 µg/ml) 22.0 36.0 22.3 45.3
Chloroquine (1.2 µg/ml) 49.5 45.0
Proguanil (>200μg/ml) 50.0 50.0
Treatment Mean % parasitaemia inhibition (in vivo)
25 64.50
Chloroquine 90.35
Similarly, Soares and colleagues evaluated hydra-
zine/hydrazide derivatives for their in vitro antima-
larial activity against Plasmodium falciparum (Chlo-
roquine-sensitive 3D-7 and Chloroquine-resistant 
W2 strains). Among all tested compounds, hydrazine 
derivatives 26, 27 demonstrated antimalarial poten-
tial better than hydrazides 28,29 and comparable to 
chloroquine (Table 4) 20.
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Table 4: In vitro antimalarial activity of compounds 26-29 
against 3D7 and W2 strains of Plasmodium falciparum.
Compounds R IC50 (3D7, µg/mL) IC50 (W2, µg/mL)
26 H 0.46 <0.39
27 Ph <0.19 <0.39
28 CO-3-Pyridyl 1.76 1.57
29 COPh 0.89 0.58
Chloroquine - <0.19 <0.39
Recently, a new class of hybrids of Atorvastatin 
(AVA) and aminoquinolines (primaquine and chloro-
quine derivatives) was achieved by Carvalho and col-
leagues. An assessment of in vitro antimalarial activ-
ity against a W2-chloroquine resistant P. falciparum 
clone, revealed that the among the synthesized com-
pounds, 1-(4-((7-chloroquinolin-4-yl)amino)butyl)-
5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyr-
role-3-carboxamide 30 emerged as the most effective 
one in terms of activity and toxicity (IC50 values in 
µM, chloroquine = 0.59, Primaquine = 1.89, Atorvas-
tatin = 10.3, 30 = 0.40)21.
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Piperazine based quinolines
In 2012, Hussain and co-workers reported the syn-
thesis of new quinoline-5,8-dione and hydroxynaph-
thoquinone derivatives. An investigation of their in 
vitro antimalarial activity against chloroquine-sen-
sitive strain NF54 of Plasmodium falciparum point-
ed out 7-bromo-2-methyl-6-(4-phenylpiperazin-1-yl)
quinoline-5,8-dione 31, the most active antimalarial 
agent (IC50 values in µM, 31 = 2.21, chloroquine = 
0.02)22.
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Quinoline–pyrimidine hybrids were synthesized by 
Pretorius and co-workers in 2013. An evaluation of 
the synthesized compounds for in vitro antimalarial 
activity against both chloroquine sensitive (D10) and 
chloroquine resistant strains (Dd2) of two clones of 
the human Plasmodium falciparum malaria, conclud-
ed that 6-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)
pyrimidine-2,4-diamine 32 (IC50 in µM: D10 = 0.070, 
Dd2 = 0.157) demonstrated significant antimalarial 
potential compared to chloroquine (IC50 in µM: D10 
= 0.040, Dd2 = 0.417)22.
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Later on, Parthiban and co-workers synthesized a 
series of chloroquinoline-4H-chromene conjugates 
incorporating piperizine or azipane tethers and eval-
uated their antimalarial activity against two Plasmo-
dium falciparum strains namely 3D7 chloroquine 
sensitive (CQS) and K1 chloroquine resistant (CQR). 
Among all the synthetic conjugates, 4-(4-(4-(7-chlo-
roquinolin-4-yl)piperazin-1-yl)phenyl)-N,5,7,8-te-
tramethyl-3,6-dinitro-4H-chromen-2-amine 33 
(IC50 in µM: 3D7 = 0.62, KI = 1.78) showed good 
antimalarial activity against two strains of P. falci-
parum (Chloroquinine IC50 in µM: 3D7 = 0.005, KI 
= 0.254)24.
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Quinolines fused with other ring systems
In 2011, Whittell et al. synthesized a series of mono- and 
di-substituted analogues of isocryptolepine and evaluated 
for in vitro antimalarial activity against chloroquine-sen-
sitive (3D7) and chloroquine-resistant (W2mef) Plas-
modium falciparum strains.Di-halogenated compounds 
were found the most potent derivatives and 8-bro-
mo-2-chloroisocryptolepine 34 displayed good antima-
larial activity against (3D7) and (W2mef) strains with IC50 
values 57 ± 14nM and 85 ± 5.6nM respectively25.
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A series of novel imidazoisoquinolinone derivatives 
were synthesized and evaluated for in vitro antima-
larial activity against chloroquine sensitive strain of 
Plasmodium falciparum by Bollini et al. 10-(2,4-di-
chloro-5-fluorobenzoyl)-2,3-dihydroimidazo[1,2-b]
isoquinolin-5(1H)-one 35 (IC50 = 0.13µM) exhibited 
good antimalarial activity comparable to chloroqui-
nine (IC50 = 0.09 µM)26.
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A series of novel N-alkyl dihydropyridoquinoxaline 
derivatives were successfully synthesized by Shekhar 
and colleagues. Ethyl 7-(4-fluorobenzyl)-10-oxo-2,3-
diphenyl-7,10-dihydropyrido[3,2-f]quinoxaline-
9-carboxylate 36 and ethyl 2,3-bis(4-fluorophenyl)-10-
oxo-7-(2,2,2-trifluoroethyl)-7,10-dihydropyrido[3,2-f]
quinoxaline-9-carboxylate 37 emerged as the most 
potent compounds as a result of their screening for in 
vitro antimalarial activity against chloroquine sensi-
tive (3D7) and drug resistant (Dd2) strains of Plasmo-
dium falciparum (Table 5)27.
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Table 5: In vitro antimalarial activity of compound 36 
and 37 against chloroquine sensitive (3D7) and drug 
resistant (Dd2) strains of Plasmodium falciparum.
Compounds R1 R2 IC50 (3D7, µM) IC50 (Dd2, µM)
ciprofloxacin - - 23.1 33.9
36 Ph 4-F-C6H4 6.94 6.27
37 4-F-C6H4 CF3 3.92 4.60
Oxoquinolines
Later on, N-aryaminobiquinoline derivatives were 
synthesized and evaluated for their antimalarial ac-
tivity against chloroquine-sensitive (3D7) strain of 
Plasmodium falciparum by Shah and colleagues. 
They concluded that N-aryaminobiquinoline deriva-
tives 38-45 have superior antimalarial activity com-
pared to chloroquine (Table 6)28.
N
O
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Table 6: Antimalarial activity of compounds 38-45 
against 3D7 strain of Plasmodium falciparum.
Compound R1 R2 IC50 (µg/mL) Compound R1 R2 IC50 (µg/mL)
38 H H 0.015 43 OCH3 OCH3 0.019
39 CH3 H 0.008 44 CH3 Br 0.012
40 OCH3 Cl 0.009 45 OCH3 Br 0.014
41 H CH3 0.005
Chloro-
quine 0.020
42 Cl CH3 0.014
Microwave assisted green syntheses and protein–li-
gand docking calculations on P. falciparum UCHL3 
protein, were carried out by Sarveswari and col-
leagues in 2015 for 4-hydroxy-3-(3-arylacryloyl)quin-
olin-2(1H)-ones and 3-(4,5-dihydro-5-aryl-1-phe-
nyl-1H-pyrazol-3-yl)-4-hydroxyquinolin-2(1H)-ones. 
Experimental results revealed that (E)-4-hydroxy-3-
(3-(thiophen-2-yl)acryloyl)quinolin-2(1H)-one 46 and 
4-hydroxy-3-(5-(4-methoxyphenyl)-1-phenyl-4,5-di-
hydro-1H-pyrazol-3-yl)quinolin-2(1H)-one 47 exhib-
ited greater potential for the inhibition of targeted 
protein as indicated by their lowest binding energy 
values, -6.59 and -8.05 Kcal/mol respectively29.
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Substituted quinolines
Akhter et al. synthesized a series of Quinoline-sub-
stituted furanone derivatives and checked their 
antimalarial activity for the inhibition of gameto-
cyte-producing P. falciparum culture lines (FDL-HD). 
Among the synthesized compound, (E)-3-((2-chloro-
6-methoxyquinolin-3-yl)methylene)-5-(4-chloro-
phenyl)furan-2(3H)-one 48 (IC50 = 0.61 μg/mL), 
(E)-3-((2-chloro-6-methoxyquinolin-3-yl)methyl-
ene)-5-(2,4-chlorophenyl)furan-2(3H)-one (IC50 = 0.50 
μg/mL)49 and (E)-3-((2-chloro-6-methoxyquinolin-
JULY - SEPTEMBER 2017  |  233
3-yl)methylene)-5-(3,4-chlorophenyl)furan-2(3H)-one 
(IC50 = 0.72 μg/mL) 50 showed good antimalarial ac-
tivity (chloroquine IC50 = 0.002 μg/mL)30.
N Cl
MeO
48
 
R
 = 4-Cl
49
 
R
 = 2,4-Cl
50
 
R
 = 3,4-Cl
O
O
R
In the same year, Vandekerckhove et al. synthesized 
a series of aminoquinolines and evaluated for their in 
vitro antimalarial activity. Antimalarial activity was 
tested against both chloroquine sensitive (NF54) and 
chloroquine resistant strains (Dd2) of Plasmodium 
falciparum. All the compounds showed moderate ac-
tivity and among them 2-methyl-3-(2-methylpyrroli-
din-1-yl)quinoline 51 (IC50 values in µM: NF54 = 13.3, 
Dd2 = 38.0) showed best results (chloroquine IC50 val-
ues in µM: NF54 = 0.021, Dd2 = 0.274)31.
N CH3
N
H3C
51
Later on, the synthesized quinoline based 1,3,4-oxa-
diazoles derivatives were screened for their antimalar-
ial potential against chloroquine and quinine sensitive 
strain of Plasmodium falciparum strain and according 
to results 1,3,4-oxadiazoles derivatives 52-56 demon-
strated excellent antimalarial activity (Table 7)32.
N
R
Cl
N
NN
OX Y
52-56
Table 7: In vitro antimalarial activity of compounds 
52-56.
Compounds 52 53 54 55 56 Quinine Chloroquine
X CH CH CH N CH - -
Y N N N CH N - -
R H CH3 OCH3 Cl Cl - -
IC50 (µM) 0.386 0.467 0.202 0.089 0.156 0.826 0.062
In the same year, Parthasaradhi and colleagues 
synthesized a series of novel 6-bromo-2-chloro-3-
(4-phenyl-[1,2,3] triazol-1-ylmethyl)-quinoline and 
its derivatives. Analysis of antimalarial activity in-
ferred that 6-bromo-2-chloro-3-((4-(3-methoxyphe-
nyl)-1H-1,2,3-triazol-1-yl)methyl)quinoline 57 (IC50 
= 5.09µM), 6-bromo-2-chloro-3-((4-(3-fluorophe-
nyl)-1H-1,2,3-triazol-1-yl)methyl)quinoline 58 (IC50 = 
3.25µM) and 6-bromo-2-chloro-3-((4-(3-bromophe-
nyl)-1H-1,2,3-triazol-1-yl)methyl)quinoline 59 (IC50 = 
2.13µM) exhibited remarkable potential against W2 
strain of Plasmodium falciparum33.
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In recent reports, Karad et at. 2016 synthesized a se-
ries of novel morpholinoquinoline based conjugates 
with pyrazoline moiety was achieved and evaluated 
for their in vitro antimalarial activity against P. falci-
parum strain by Karad and colleagues. Seven conju-
gates 60-66 exhibited excellent in vitro antimalarial 
activity compared to reference drugs (Table 8)34.
N N
NN
R2
O
R1
60-66
Table 8: In vitro antimalarial activity of compounds 
60-66 against P. falciparum strain.
Compound R1 R2 IC50 (µM) Compound R1 R2 IC50 (µM)
60 OMe COMe 0.034 65 Br CHO 0.040
61 Br COMe 0.018 66 Cl CHO 0.028
62 Br CSNH2 0.044 Chloroquine - - 0.062
63 OMe 4-F-C6H4 0.051 Quinine - - 0.826
64 Br 4-F-C6H4 0.015
2.6 Miscellenous quinolines
In 2012, Patti et al. reported the synthesis and in 
vitro antimalarial activity of 2-ferrocenylquinoline 
derivatives against chloroquine-susceptible D10 and 
chloroquine-resistant W2 strains of Plasmodium 
falciparum. Among all the synthesized compounds, 
2-ferrocenylquinoline derivative 67 showed good an-
timalarial activity against both chloroquine-suscep-
tible D10 and chloroquine-resistant W2 strains of 
Plasmodium falciparum with IC50 values 14.8µM and 
13.8µM respectively35.
N
H
Me2N
Fe
67
Vandekerckhove et al. synthesized a series of amino-
quinolines and evaluated for their in vitro antimalarial 
activity. Antimalarial activity was tested against both 
chloroquine sensitive (NF54) and chloroquine resist-
ant strains (Dd2) of Plasmodium falciparum. All the 
compounds showed moderate activity and among them 
4-(quinolin-5-ylamino)butan-1-ol 68 (IC50 values: NF54 
= 19.9 µM, Dd2 = 49.0) showed best results (Quinoline 
IC50 values: NF54 = 0.021 µM, Dd2 = 0.274)31.
N
HN
OH
68
Later on, Parthiban and co-workers synthesized a 
series of chloroquinoline-4H-chromene conjugates 
incorporating piperizine or azipane tethers and eval-
uated their antimalarial activity against two Plasmo-
dium falciparum strains namely 3D7 chloroquine 
sensitive (CQS) and K1 chloroquine resistant (CQR). 
Among all the synthetic conjugates, 6-chloro-4-(4-(4-
(7-chloroquinolin-4-yl)-1,4-diazepan-1-yl)phenyl)-N-
methyl-3-nitro-4H-chromen-2-amine 69 (IC50 values: 
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3D7 = 0.29 µM, KI = 0.496) showed good antimalarial 
activity against two strains (3D7 and K1) of P. falci-
parum (Quinoline IC50 values: 3D7 = 0.005 µM, KI = 
0.254)21.
N
N N O
NHMeO2N
Cl
Cl
69
In the same year, Shah et al. reported the synthe-
sis of a series of quinoline-pyrimidine linked calix[4]
arene derivatives with different functional groups. 
Results of antimalarial activity assay showed that 
8-hydroxy quinoline linked calix[4]arene derivative 
70 have good antimalarial activity with IC50 values of 
0.073 µg/ml comparable to the standard drug chloro-
quine (IC50 0.02 µg/mL)36.
OO OO
X
O
O X XO XO
N
O
70
 
X
 =
CONCLUSION
Quinoline and its derivatives are important antima-
larial agents. So, keeping their significance we have 
reviewed a variety of quinoline based compounds re-
ported during the last five years as potent antimalarial 
agents. We hope so that this effort may prove stimula-
tion for the future pharmaceutical chemists.
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